US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Niagen Bioscience

5.02

+0.15503.19%

Volume:513.96K

Turnover:2.54M

Market Cap:400.80M

PE:21.35

High:5.05

Open:4.83

Low:4.74

Close:4.86

52wk High:14.69

52wk Low:4.74

Shares:79.92M

Float Shares:51.41M

Volume Ratio:0.94

T/O Rate:1.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2349

EPS(LYR):0.1100

ROE:38.90%

ROA:15.60%

PB:5.67

PE(LYR):45.59

Loading ...

Overview Company News Filings

Niagen Bioscience Sponsors Inaugural NAD for Health Conference in Copenhagen

Does Niagen Bioscience (NAGE) Still Hold a Defensible NAD+ Moat Ahead of Its 2025 Earnings Call?

Simply Wall St.

Press Release: Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

BRIEF-Niagen Bioscience Inc - Partners With Truemed To Expand HSA/FSA Access For Tru Niagen

Niagen Bioscience Inc - Partners With Truemed to Expand Hsa/FSA Access for Tru Niagen

THOMSON REUTERS

Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast

MT Newswires Live

Niagen Bioscience Acquires Core Nicotinamide Riboside Patent Portfolio

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (Nr) Patent Portfolio From Queen’s University Belfast

THOMSON REUTERS

Niagen Bioscience management to meet with Roth Capital

Niagen Bioscience Announces $10 Million Share Repurchase Program

Niagen Bioscience CFO Pamir Ozan Acquires Common Shares

Correction: Niagen Says Long COVID Trial Exploring Supplement Failed to Show 'Statistically Significant Differences' in Meeting Endpoints Versus Placebo Groups

MT Newswires Live

Niagen Bioscience announces results of Niagen supplementation in long COVID

Niagen Bioscience Reports Clinical Trial Shows Niagen Supplement Boosts NAD+ and Eases Long COVID Symptoms

We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve

Simply Wall St.

Niagen Bioscience Approves $10 Million Stock Buyback Program

MT Newswires Live

Stock Track | Niagen Bioscience Soars 6.25% Following $10 Million Share Repurchase Announcement

Stock Track | Niagen Bioscience Soars 6.25% on $10 Million Share Repurchase Program Announcement

Niagen Bioscience Announces $10 Million Share Buyback

Stock Track | Niagen Bioscience Soars 6.10% Pre-market on $10 Million Share Repurchase Announcement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NAGE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NAGE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","market":"US","secType":"STK","nameCN":"Niagen Bioscience","latestPrice":5.015,"timestamp":1771871439083,"preClose":4.86,"halted":0,"volume":513955,"delay":0,"changeRate":0.031893004115226206,"floatShares":51414700,"shares":79919957,"eps":0.234893,"marketStatus":"Trading","change":0.155,"latestTime":"02-23 13:30:45 EST","open":4.83,"high":5.0457,"low":4.737,"amount":2538116.913865,"amplitude":0.063519,"askPrice":5.02,"askSize":103,"bidPrice":5.01,"bidSize":344,"shortable":3,"etf":0,"ttmEps":0.234893,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":4.86,"preHourTrading":{"tag":"盘前","latestPrice":4.83,"preClose":4.86,"latestTime":"09:29 EST","volume":8078,"amount":39341.7615612,"timestamp":1771856999999,"change":-0.03,"changeRate":-0.006173,"amplitude":0.024691},"postHourTrading":{"tag":"盘后","latestPrice":4.86,"preClose":4.86,"latestTime":"19:24 EST","volume":13388,"amount":65075.3395,"timestamp":1771633448987,"change":0,"changeRate":0,"amplitude":0.002058},"volumeRatio":0.939825,"impliedVol":1.6258,"impliedVolPercentile":0.9274},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","floatShares":51414700,"roa":"15.60%","roe":"38.90%","lyrEps":0.11,"volumeRatio":0.939825,"shares":79919957,"dividePrice":0,"high":5.0457,"amplitude":0.063519,"preClose":4.86,"low":4.737,"week52Low":4.737,"pbRate":"5.67","psRate":"3.21","week52High":14.69,"institutionHeld":0,"latestPrice":5.015,"committee":0.53915,"eps":0.234893,"divideRate":0,"volume":513955,"delay":0,"ttmEps":0.234893,"open":4.83,"prevYearClose":6.36,"prevWeekClose":4.86,"prevMonthClose":5.99,"prevQuarterClose":6.36,"fiveDayClose":5.14,"twentyDayClose":6.01,"sixtyDayClose":6.86,"earningDate":1772553600000,"earningTime":"盘后"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAGE\",params:#limit:5,,,undefined,":[{"date":"2026-03-04","symbol":"NAGE","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":0.01,"defaultRemindTime":1772658000000,"name":null,"time":"Post Market","dateTimestamp":1772600400000,"actualEps":null},{"market":"US","date":"2025-11-04","symbol":"NAGE","fiscalQuarterEnding":"2025/09","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":0.05},{"market":"US","date":"2025-08-06","symbol":"NAGE","fiscalQuarterEnding":"2025/06","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-05-07","symbol":"NAGE","fiscalQuarterEnding":"2025/03","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-03-04","symbol":"NAGE","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741064400000,"reportTimeType":"post","actualEps":0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAGE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAGE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1748322000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NAGE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NAGE","date":"2026-02-20","current":21.350147,"percent":0,"low":19.366604,"twenty":25.843047,"median":43.816458,"eighty":64.134289,"high":80.643552,"avg":45.211243,"sd":18.154851,"marketCap":395640346},"quantilePoints":[{"date":"2025-03-21","current":69.624479,"twenty":69.806742,"median":70.080136,"eighty":70.353531,"marketCap":595289295},{"date":"2025-03-28","current":67.346191,"twenty":68.676711,"median":69.624479,"eighty":70.371757,"marketCap":575809933},{"date":"2025-04-04","current":60.420196,"twenty":62.662031,"median":67.938546,"eighty":69.697384,"marketCap":516592673},{"date":"2025-04-11","current":51.67157,"twenty":54.861173,"median":62.880747,"eighty":69.551574,"marketCap":441791924},{"date":"2025-04-17","current":59.600012,"twenty":54.815607,"median":61.696037,"eighty":69.259953,"marketCap":509580103},{"date":"2025-04-25","current":67.255059,"twenty":55.043436,"median":62.151694,"eighty":68.530901,"marketCap":575030758},{"date":"2025-05-02","current":68.895427,"twenty":55.954751,"median":62.880747,"eighty":69.442216,"marketCap":589055899},{"date":"2025-05-09","current":51.710369,"twenty":55.954751,"median":65.022337,"eighty":70.535794,"marketCap":729374756},{"date":"2025-05-16","current":58.761783,"twenty":54.815607,"median":62.789615,"eighty":69.71561,"marketCap":828834951},{"date":"2025-05-23","current":56.859021,"twenty":55.043436,"median":61.650471,"eighty":69.624479,"marketCap":801996485},{"date":"2025-05-30","current":60.552618,"twenty":55.242319,"median":61.364091,"eighty":69.478669,"marketCap":854094682},{"date":"2025-06-06","current":64.414107,"twenty":55.822209,"median":61.604905,"eighty":69.296406,"marketCap":908560979},{"date":"2025-06-13","current":79.132535,"twenty":56.409541,"median":62.698483,"eighty":70.55402,"marketCap":1116164400},{"date":"2025-06-20","current":77.117845,"twenty":56.623974,"median":63.647427,"eighty":71.912091,"marketCap":1087747202},{"date":"2025-06-27","current":77.341699,"twenty":56.791865,"median":65.523561,"eighty":75.181504,"marketCap":1090904668},{"date":"2025-07-03","current":71.129739,"twenty":57.426855,"median":65.645306,"eighty":75.483707,"marketCap":1003284974},{"date":"2025-07-11","current":65.981088,"twenty":58.471876,"median":66.48476,"eighty":75.192697,"marketCap":930663244},{"date":"2025-07-18","current":57.950311,"twenty":58.471876,"median":65.645306,"eighty":75.114348,"marketCap":817389135},{"date":"2025-07-25","current":51.87826,"twenty":56.758286,"median":65.022337,"eighty":74.190401,"marketCap":731742856},{"date":"2025-08-01","current":52.325969,"twenty":55.224884,"median":64.358143,"eighty":72.732275,"marketCap":738057789},{"date":"2025-08-08","current":43.320593,"twenty":54.318273,"median":62.947882,"eighty":72.15947,"marketCap":768030786},{"date":"2025-08-15","current":43.771379,"twenty":53.985743,"median":62.607352,"eighty":71.628921,"marketCap":776022782},{"date":"2025-08-22","current":44.041851,"twenty":52.415511,"median":61.650471,"eighty":71.37484,"marketCap":780817979},{"date":"2025-08-29","current":44.267244,"twenty":51.68709,"median":61.280145,"eighty":71.129739,"marketCap":784813977},{"date":"2025-09-05","current":42.013311,"twenty":50.71606,"median":60.552618,"eighty":71.083855,"marketCap":744853999},{"date":"2025-09-12","current":43.365671,"twenty":45.745824,"median":60.318517,"eighty":70.845641,"marketCap":768829986},{"date":"2025-09-19","current":45.709762,"twenty":45.222912,"median":59.50888,"eighty":70.6087,"marketCap":810388363},{"date":"2025-09-26","current":42.419019,"twenty":45.024566,"median":58.520194,"eighty":70.371757,"marketCap":752046795},{"date":"2025-10-03","current":33.268051,"twenty":44.46559,"median":56.887002,"eighty":69.697384,"marketCap":589809282},{"date":"2025-10-10","current":34.079467,"twenty":44.02382,"median":56.607185,"eighty":69.623328,"marketCap":604194874},{"date":"2025-10-17","current":33.448366,"twenty":43.66319,"median":55.29204,"eighty":69.583421,"marketCap":593006080},{"date":"2025-10-24","current":33.448366,"twenty":43.41075,"median":54.929521,"eighty":69.405763,"marketCap":593006080},{"date":"2025-10-31","current":32.050928,"twenty":43.28453,"median":54.228731,"eighty":69.187048,"marketCap":568230894},{"date":"2025-11-07","current":25.87441,"twenty":42.455082,"median":54.050915,"eighty":68.822522,"marketCap":528588317},{"date":"2025-11-14","current":27.403352,"twenty":42.022327,"median":53.333314,"eighty":68.390298,"marketCap":559823081},{"date":"2025-11-21","current":26.30565,"twenty":34.151593,"median":52.437896,"eighty":67.731548,"marketCap":537398122},{"date":"2025-11-28","current":26.540872,"twenty":33.854074,"median":52.018169,"eighty":67.346191,"marketCap":542203471},{"date":"2025-12-05","current":26.266446,"twenty":33.628681,"median":51.67157,"eighty":67.255059,"marketCap":536597231},{"date":"2025-12-12","current":25.992021,"twenty":33.448366,"median":50.903505,"eighty":67.255059,"marketCap":530990991},{"date":"2025-12-19","current":25.482373,"twenty":32.772186,"median":49.393282,"eighty":66.988433,"marketCap":520579403},{"date":"2025-12-26","current":25.913613,"twenty":32.474667,"median":46.160548,"eighty":66.182557,"marketCap":529389208},{"date":"2026-01-02","current":24.933522,"twenty":30.002996,"median":45.709762,"eighty":65.94751,"marketCap":509366924},{"date":"2026-01-09","current":25.717595,"twenty":27.520963,"median":45.43929,"eighty":65.757233,"marketCap":525384751},{"date":"2026-01-16","current":24.737504,"twenty":27.019156,"median":45.168818,"eighty":65.594939,"marketCap":505362467},{"date":"2026-01-23","current":24.619893,"twenty":26.909386,"median":44.627874,"eighty":65.546241,"marketCap":502959792},{"date":"2026-01-30","current":23.482987,"twenty":26.540872,"median":44.492638,"eighty":65.122582,"marketCap":479733942},{"date":"2026-02-06","current":20.111473,"twenty":26.282128,"median":44.267244,"eighty":64.478311,"marketCap":410857283},{"date":"2026-02-13","current":19.954658,"twenty":25.944976,"median":44.008043,"eighty":64.391721,"marketCap":407653717},{"date":"2026-02-20","current":19.366604,"twenty":25.843047,"median":43.816458,"eighty":64.134289,"marketCap":395640346}],"updateTime":1771871445596},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NAGE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610265588","title":"Niagen Bioscience Sponsors Inaugural NAD for Health Conference in Copenhagen","url":"https://stock-news.laohu8.com/highlight/detail?id=2610265588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610265588?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:34","pubTimestamp":1770644058,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL38XkG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4183","BK4121"],"gpt_icon":0},{"id":"2610957400","title":"Does Niagen Bioscience (NAGE) Still Hold a Defensible NAD+ Moat Ahead of Its 2025 Earnings Call?","url":"https://stock-news.laohu8.com/highlight/detail?id=2610957400","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610957400?lang=en_us&edition=fundamental","pubTime":"2026-02-08 23:10","pubTimestamp":1770563444,"startTime":"0","endTime":"0","summary":"Niagen Bioscience, Inc. (NASDAQ: NAGE) previously announced it will report fourth quarter and fiscal 2025 results and host an investor conference call on March 4, 2026, including a general business update following the release of its earnings after market close.\nThe company’s position as a leading NAD+ player, with FDA-recognized Niagen® and defended patents around nicotinamide riboside, highlights a reinforced regulatory moat and product pipeline momentum.\nWe’ll now examine how the upcoming...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/does-niagen-bioscience-nage-still-hold-a-defensible-nad-moat","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/does-niagen-bioscience-nage-still-hold-a-defensible-nad-moat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NAGE","NAD"],"gpt_icon":0},{"id":"2609459676","title":"Press Release: Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2609459676","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609459676?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:32","pubTimestamp":1770384720,"startTime":"0","endTime":"0","summary":"Niagen Bioscience, Inc. , the global authority on NAD+  with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, March 4, 2026.Webcast link: Niagen Bioscience Fourth Quarter and Fiscal Year 2025 Earnings Conference Call. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.At the heart of its clinically proven produc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4099","BK4121","BK4588","BK4585","BK4555","NAGE","TM","03160","BK4232","R","BK4604"],"gpt_icon":0},{"id":"2603247988","title":"BRIEF-Niagen Bioscience Inc - Partners With Truemed To Expand HSA/FSA Access For Tru Niagen","url":"https://stock-news.laohu8.com/highlight/detail?id=2603247988","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603247988?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:37","pubTimestamp":1768484247,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Inc - Partners With Truemed To Expand HSA/FSA Access For Tru NiagenJan 15 (Reuters) - Niagen Bioscience Inc NAGE.O:NIAGEN BIOSCIENCE INC - PARTNERS WITH TRUEMED TO EXPAND HSA/F","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2603988267","title":"Niagen Bioscience Inc - Partners With Truemed to Expand Hsa/FSA Access for Tru Niagen","url":"https://stock-news.laohu8.com/highlight/detail?id=2603988267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603988267?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:36","pubTimestamp":1768484191,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2593313431","title":"Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast","url":"https://stock-news.laohu8.com/highlight/detail?id=2593313431","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593313431?lang=en_us&edition=fundamental","pubTime":"2025-12-23 00:42","pubTimestamp":1766421739,"startTime":"0","endTime":"0","summary":"Niagen Bioscience  said Monday its ChromaDex subsidiary has acquired from Queen's University Belfast the patent portfolio for nicotinamide riboside previously shared or licensed to ChromaDex.Under an assignment agreement, the university assigned to ChromaDex all of its right, title and interest in the patent rights in exchange for an upfront payment of about $1 million, annual payments of $500,000 and 35,000 British pounds  from 2026 through 2038, and one-time payments of $1.5 million and $2 million in 2035 and 2038 respectively, Niagen said in its filing with the US Securities and Exchange Commission.Niagen said the acquired portfolio consists of the core patents supporting the production, composition and commercial use of nicotinamide riboside.The assignment agreement, executed by ChromaDex and the university last week, terminated their 2015 licensing and joint ownership agreement, Niagen said.Shares of Niagen were up more than 7% in recent Monday trading.Price: 6.98, Change: +0.46, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2593438853","title":"Niagen Bioscience Acquires Core Nicotinamide Riboside Patent Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2593438853","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593438853?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:32","pubTimestamp":1766410332,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. has acquired a comprehensive portfolio of patents covering nicotinamide riboside  and its salt forms from Queen’s University Belfast. This transaction consolidates ownership of key intellectual property related to NR production, composition, and commercial use, making Niagen Bioscience the sole owner of these assets and further strengthening its leadership position in the NAD+ industry.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire  on December 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL3djM38:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2593480048","title":"Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (Nr) Patent Portfolio From Queen’s University Belfast","url":"https://stock-news.laohu8.com/highlight/detail?id=2593480048","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593480048?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:32","pubTimestamp":1766410320,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA1TMGXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2586440357","title":"Niagen Bioscience management to meet with Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2586440357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586440357?lang=en_us&edition=fundamental","pubTime":"2025-11-26 02:35","pubTimestamp":1764095741,"startTime":"0","endTime":"0","summary":"Meeting to be held in Chicago on December 3 hosted by Roth Capital. Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-management-to-meet-with-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-management-to-meet-with-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2584926062","title":"Niagen Bioscience Announces $10 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926062","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926062?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:55","pubTimestamp":1763571341,"startTime":"0","endTime":"0","summary":"Nov 6 (Reuters) - Niagen Bioscience Inc ::*NIAGEN BIOSCIENCE ANNOUNCES $10 MILLION SHARE REPURCHASE PROGRAM  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202513:07:00.187 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD5NxnTV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2584265476","title":"Niagen Bioscience CFO Pamir Ozan Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584265476","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584265476?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:23","pubTimestamp":1763385834,"startTime":"0","endTime":"0","summary":"Ozan Pamir, Chief Financial Officer of Niagen Bioscience Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLbZdDVx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Niagen Bioscience CFO Pamir Ozan Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2583942625","title":"Correction: Niagen Says Long COVID Trial Exploring Supplement Failed to Show 'Statistically Significant Differences' in Meeting Endpoints Versus Placebo Groups","url":"https://stock-news.laohu8.com/highlight/detail?id=2583942625","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583942625?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:40","pubTimestamp":1763048453,"startTime":"0","endTime":"0","summary":"Niagen Bioscience  said Wednesday that a clinical trial showed that daily supplement of its patented nicotinamide riboside Niagen did not show \"statistically significant differences\" in meeting primary or secondary endpoints in patients with long COVID-19 relative to placebo groups.The 58-participant placebo-controlled 24-week study showed that the supplement increased NAD+ co-enzyme levels up to 3.1-fold and improved functioning, fatigue, depression, and sleep quality, when compared to their baseline levels, in some individuals, the company said.The study's inconclusive results were \"likely due to the small sample size and high dropout rates,\" the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2583536862","title":"Niagen Bioscience announces results of Niagen supplementation in long COVID","url":"https://stock-news.laohu8.com/highlight/detail?id=2583536862","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583536862?lang=en_us&edition=fundamental","pubTime":"2025-11-13 10:25","pubTimestamp":1763000710,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NAGE) shared promising results from the first-of-its-kind clinical trial published today in The Lancet peer-reviewed journal eCl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-announces-results-of-niagen-supplementation-in-long-covid-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-announces-results-of-niagen-supplementation-in-long-covid-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2583580313","title":"Niagen Bioscience Reports Clinical Trial Shows Niagen Supplement Boosts NAD+ and Eases Long COVID Symptoms","url":"https://stock-news.laohu8.com/highlight/detail?id=2583580313","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583580313?lang=en_us&edition=fundamental","pubTime":"2025-11-13 08:52","pubTimestamp":1762995153,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. has announced results from the first-ever randomized controlled trial examining Niagen, the company's patented nicotinamide riboside  supplement, in individuals with long COVID. The findings, published in The Lancet's eClinicalMedicine journal, indicate that daily supplementation with Niagen significantly increased NAD+ levels and was associated with within-group improvements in executive functioning, fatigue, depression, and sleep quality compared to baseline. The 24-week, double-blind, placebo-controlled study involved 58 non-hospitalized adults experiencing persistent symptoms following COVID-19 infection. Results from this clinical trial have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL3DW3yZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2582688283","title":"We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve","url":"https://stock-news.laohu8.com/highlight/detail?id=2582688283","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582688283?lang=en_us&edition=fundamental","pubTime":"2025-11-11 18:34","pubTimestamp":1762857277,"startTime":"0","endTime":"0","summary":"Even though Niagen Bioscience, Inc. ( NASDAQ:NAGE ) posted strong earnings, investors appeared to be underwhelmed. We...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nage/niagen-bioscience/news/we-think-niagen-biosciences-nasdaqnage-profit-is-only-a-base","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nage/niagen-bioscience/news/we-think-niagen-biosciences-nasdaqnage-profit-is-only-a-base","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4121","TSYW.SI","QID","QLD","USAW.SI","USJW.SI","BK4211","FCF","NQmain","MNQmain","NAGE","NVIW.SI","TQQQ",".IXIC","SQQQ","PSQ"],"gpt_icon":1},{"id":"2581011203","title":"Niagen Bioscience Approves $10 Million Stock Buyback Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2581011203","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581011203?lang=en_us&edition=fundamental","pubTime":"2025-11-07 03:19","pubTimestamp":1762456756,"startTime":"0","endTime":"0","summary":"Niagen Bioscience  said Thursday its board authorized a stock buyback program of up to $10 million over about 24 months.The company may repurchase shares through open market or private transactions, depending on market conditions and legal requirements, it said.Price: 6.82, Change: -0.06, Percent Change: -0.94","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"1199485103","title":"Stock Track | Niagen Bioscience Soars 6.25% Following $10 Million Share Repurchase Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1199485103","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199485103?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:06","pubTimestamp":1762441565,"startTime":"0","endTime":"0","summary":"Shares of Niagen Bioscience (NAGE) are soaring 6.25% in early trading on Thursday, building on the momentum from pre-market activity. The surge comes in response to the company's announcement of a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NAGE"],"gpt_icon":0},{"id":"1171120965","title":"Stock Track | Niagen Bioscience Soars 6.25% on $10 Million Share Repurchase Program Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1171120965","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171120965?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:06","pubTimestamp":1762441564,"startTime":"0","endTime":"0","summary":"Shares of Niagen Bioscience (NAGE) are soaring 6.25% in pre-market trading on Thursday, following the company's announcement of a $10 million share repurchase program. This significant uptick...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NAGE"],"gpt_icon":0},{"id":"2581094432","title":"Niagen Bioscience Announces $10 Million Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2581094432","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581094432?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:29","pubTimestamp":1762439353,"startTime":"0","endTime":"0","summary":"Niagen Bioscience ( ($NAGE) ) has provided an announcement. On November 6, 2025, Niagen Bioscience announced that its Board of Directors approved a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/niagen-bioscience-announces-10-million-share-buyback?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/niagen-bioscience-announces-10-million-share-buyback?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"1149417785","title":"Stock Track | Niagen Bioscience Soars 6.10% Pre-market on $10 Million Share Repurchase Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1149417785","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149417785?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:46","pubTimestamp":1762436815,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NAGE) shares surged 6.10% in pre-market trading on Thursday, following the company's announcement of a $10 million share repurchase program. This strategic move has sparked...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NAGE"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}]}}